PLEURAL MESOTHELIOMA: ETIOLOGY, INCIDENCE, DIAGNOSIS, TREATMENT AND SURVIVAL


Cite item

Full Text

Abstract

The incidence rate of malignant pleural mesothelioma accounts for 0.2 cases per 100,000 population among men and 0.1 cases among women in Russia, and 0.88 and 0.67 cases respectively in Altai Territory. Recently, there has been a growing number of the incidences due to a widespread use of asbestos in the 70th years of the last century. Malignant mesothelioma is distinguished by a prolonged latency period, and constitutes a highly aggressive tumor. By now, the diagnosis of pleural mesothelioma still remains a problem. CT and US-scans are used together with chest X-ray. Morphological confirmation of tumor (biopsy and cytologic examination of exudation complemented by immunocytochemical technique) is obligatory. Treatment of malignant mesothelioma mostly includes chemotherapy with cisplatin and pemetrexed. Radical surgery is more frequently impossible considering a diffusion growth of mesothelioma. Radiotherapy is used as prevention, and applied to a puncture point and post-surgery to prevent local recurrence. The life expectancy of the patients with malignant pleural is poor: from 4 to 12 months with an average of 7 months. Only 26.5% of such patients have life expectancy longer than one year, and 6.8% of such patients live longer than 3 years. Maximum life expectancy of patients with malignant pleural mesothelioma accounts for 44 months. These are women with accumulation of fluid diagnosed in the left-sided pleural space with epithelioid mesothelioma.

About the authors

A. F Lazarev

Алтайский филиал ФГБУ «Российский онкологический научный центр им. Н.Н.Блохина» РАМН; КГБУЗ «Алтайский краевой онкологический диспансер»

O. G Grigoruk

Алтайский филиал ФГБУ «Российский онкологический научный центр им. Н.Н.Блохина» РАМН; КГБУЗ «Алтайский краевой онкологический диспансер»

Email: cytolakod@rambler.ru
канд. биол. наук, зав. отд-нием клинической лабораторной диагностики 656049, г. Барнаул, ул. Никитина, 77

L. M Bazulina

КГБУЗ «Алтайский краевой онкологический диспансер»

P. N Muzalevskiy

Алтайский филиал ФГБУ «Российский онкологический научный центр им. Н.Н.Блохина» РАМН; КГБУЗ «Алтайский краевой онкологический диспансер»

V. Yu Kravtsov

ФГБУ «Всероссийский центр экстренной и радиационной медицины им. А.М.Никифорова» МЧС России

References

  1. Kristmann M., Muller K.M. Malignes mesotheliom der pleura, des pericards und des peritoneums: Teil 1:Atiologia, pathogenese, pathologie. Chirurg. 2000; 71(8): 877-86.
  2. Baker P.M., Clement P.B., Young R.N. Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am. J. Clin. Pathol. 2005; 123: 724-37.
  3. Delgermaa V., Takahashi K., Park E. et al. Global mesothelioma deaths reported to the World Health Organisation between 1994 and 2008. Bull. World Hlth Org. 2011; 89: 716-24.
  4. Davidson B., Reich R., Lazarovici P. et al. Expression of thenerve growth factor receptors TrkA and p75 in malignant mesothelioma. Lung Cancer. 2004; 44: 159-65.
  5. Britton M. The epidemiology of mesothelioma. Semin. Oncol. 2002; 29: 18-25.
  6. Parker C., Neville E. Lung cancer management of malignant mesothelioma. Thorax. 2003; 58 (4): 809 — 13.
  7. Pass H.I., Carbone M., Chahinian A.P. Malignant mesothelioma. In: Cancer medicine. 7th ed. Hamilton: BC Decker Inc.; 2006; 1225—36.
  8. Hughes R.S. Malignant pleural mesothelioma. Am. J. Med. Sci. 2005; 329: 29-44.
  9. Yang H., Testa J.R., Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr. Treat. Options Oncol. 2008; 9: 147-57.
  10. Robinson B.W., Lake R.A. Advances in malignant mesothelioma. N. Engl. J. Med. 2005; 353 (15): 1591—03.
  11. Статистика злокачественных новообразований в России и странах СНГ в 2007 г. Под ред. академика РАН и РАМН М.И. Давыдова и д-ра биол. наук Е.М. Аксель. Вестник РОНЦ им. Н.Н.Блохина РАМН. 2009; 20 (3): Приложение.
  12. Бычков М.Б., Большакова С.А., Бычков Ю.М. Мезотелиома плевры: современная тактика лечения. Современная онкология. 2005; 7 (3): 142-4.
  13. Craighead J. Epidemiology of mesothelioma and historical background. Recent Results Cancer Res. 2011; 189: 13-25.
  14. Заридзе Д.Г. Эпидемиология рака. В кн.: Профилактика, ранняя диагностика и лечение злокачественных новообразований. Лекционный курс в рамках подпрограммы «О мерах по развитию онкологической помощи населению Российской Федерации». М.: 2005; 23-49.
  15. Britton M. The epidemiology of mesothelioma. Semin. Oncol. 2002; 29: 18-25.
  16. Davidson B. Malignant effusions. From diagnosis to biology. Diagn. Cytopathol. 2004; 31: 246—54.
  17. Lo'pez-Ri'os F., Illei P.B., Rusch V., Ladanyi M. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet. 2004; 364: 1157-66.
  18. Музалевский П.Н. Особенности распространения мезотели-омы с учетом экзогенных факторов на модели Алтайского края: Дис. Барнаул; 2006.
  19. Champbell N., Kindler H. Update on malignant pleural mesothelioma. Semin Respir Crit Care Med. 2011; 32: 102-10.
  20. Scherpereel A., Astoul P., Baas P. et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleura mesothelioma. Eur. Repir. J. 2010; 35: 479-95.
  21. Davies H.E., SadlerR.S., Bielsa S. et al. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am. J. Respir. Crit. Care Med. 2009; 180 (5): 437—44.
  22. Gueugnon F., Leclercq S., Blanquart C. et al. Identification of novel markers for the diagnosis of malignant pleural mesothelioma. Am.J. Pathol. 2011; 178(3): 1033—42.
  23. Van der Bij S., Schaake E., Koffijberg H. et al. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br. J. Cancer. 2011; 104(8): 1325—33.
  24. Gill R. Imaging of mesothelioma. Recent Results Cancer Res. 2011; 189: 27-55.
  25. Hasegawa S., Kondo N., Matsumoto S. et al. Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal fordiagnostic total parietal pleurectomy. Int. J. Clin. Oncol. 2012; 17(1): 33—9.
  26. Pinelli V., Laroumagne S., Sakr L. et al. Pleural fluid cytologi-cal yield and visceral pleural invasion in patients with epithelioid malignantpleural mesothelioma. J. Thorac. Oncol. 2012; 7(3): 595—8.
  27. Григорук О.Г., Лазарев А.Ф., Богатырёв В.Н. Дифференциальная цитологическая диагностика плевритов. Барнаул: ОАО «ИПП «Алтай», 2012: 54—90.
  28. Attanous R., Gibbs A. The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma. Histopathology. 2006; 53: 340-4.
  29. Hopper C., Lee Y., Maskell N. Investigation of a unilateral pleural effusion in adults. British Thoracic Society pleural disease guideline. Thorax. 2010; 65: 4-17.
  30. Husain A., Colby T., Ordonez N. et al. Guidelines for pathologic diagnosis of malignant mesothelioma. Arch. Pathol. Lab. Med. 2012; 136: 1-21.
  31. Sun Y., Wu G.P., Fang C.Q., Liu S.L. Diagnostic utility of MOC- 31, HBME-1 and MOC-31 mRNA in distinguishing between carcinoma cells and reactive mesothelial cells in pleural effusions. Acta Cytol. 2009; 53(6): 619—24.
  32. Tischoff I., Neid M., Neumann V., Tannapfel A. Pathological diagnosis and differential diagnosis of mesothelioma. Recent Results Cancer Res. 2011; 189: 57-77.
  33. Rice D. Surgical therapy of mesothelioma. Recent Results Cancer Res. 2011; 189: 97-125.
  34. Soysal O., Karaoglanoglu N., Demiracan S. Pleurectomy/decortication for palliation in malignant pleural mesothelioma. Results of surgery. Eur. J. Cardiothorac. Surg. 1997; 11: 210-13.
  35. Бычков М.Б., Карпенко Т.Д. Мезотелиома плевры (диагностика, лечение). Сибирский онкологический журнал. 2013; Приложение 2: Материалы Российской научно-практической конференции «Современные аспекты диагностики и лечения рака легкого» г. Томк: 17—8.
  36. Thödtmann R., Depenbrock H., Dumez H. et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J. Clin. Oncol. 1999; 17: 3009-16.
  37. Vogelzang N., Rusthoven J., Symanowski J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesotheliomna. J. Clin. Oncol. 2003; 21: 2636-44.
  38. Grosso F., Scagliotti G. Systematic treatment of malignant pleural mesothelioma. Fut. Oncol. 2012; 8: 293-305.
  39. Manegold C., Symanowski J., Gatzemeier U. et al. Second line (post study) chemotherapy received by patients treated in the phase III trial pemetrexed plus cisplatin alone in malignant pleural mesothelioma. Ann. Oncol. 2005; 16: 923-7.
  40. Neumann V., Löseke S., Nowak D. et al. Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health Dtsch Arztebl Int. 2013; 110(18): 319—26.
  41. Dhalluin X., Scherpereel A. Chemotherapy and Radiotherapy for mesothelioma. Recent Results Cancer Res. 2011; 189: 127-47.
  42. De Rienzo A., Dong L., Yeap B.Y. et al. Fine-needle aspiration biopsies for gene expression ratio-based diagnostic and prognostic tests in malignant pleural mesothelioma. Clin. Cancer. Res. 2011; 17(2): 310—16.
  43. Sugarbaker D.J., Wolf A.S., Chirieac L.R. et al. Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy. Eur. J. Cardiothorac. Surg. 2011; 2: 38—41.
  44. Roe O.D., Creaney J., Lundgren S. et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer. 2008; 61(2): 235—43.
  45. Schipper P.H., Nichols F.C., Thomse K.M. et al. Malignant pleural mesothelioma: surgical management in 285. Ann. Thorac. Surg. 2008; 85: 257-64.

Copyright (c) 2013 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies